Company:  VERTEX PHARMACEUTICALS IN ... (VRTX)
Form Type:  4
Filing Date:  8/3/2021 
CIK:  0000875320 
Address:  50 NORTHERN AVENUE 
City, State, Zip:  BOSTON, Massachusetts 02210 
Telephone:  (617) 341-6393 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$191.13  
Change: 
1.02 (0.54%)  
Trade Time: 
11:00 AM EST  
Market Cap: 
$48.60B
Trade VRTX now with 

© 2021  
Description of Business
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. Cystic Fibrosis Our goal is to develop treatment regimens that will provide benefits to all people with cystic fibrosis, or CF, and will enhance the benefits currently provided to people taking our medicines. Our marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Our triple combination regimen, TRIKAFTA/KAFTRIO, was approved in 2019 in the United States, or U.S., and in 2020 in the European Union, or E.U. Collectively, our four medicines are approved to treat the majority of the approximately 83,000 people with CF in North America, Europe and Australia.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    REPORTING OWNERS
    SIGNATURES